SCHEMBL1472888

SCHEMBL1472888

Cc1ccc(S(=O)(=O)OC(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.48
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA5A P35218 2/20 0.45
CA9 Q16790 2/20 0.45
CA12 O43570 1/20 0.45
CA3 P07451 1/20 0.45
CA6 P23280 1/20 0.45
CA7 P43166 1/20 0.45
CA5B Q9Y2D0 1/20 0.45
TLR9 Q9NR96 1/20 0.43
VDR P11473 1/20 0.43
BCHE P06276 2/20 0.43
ACHE P22303 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 4/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL415055 0.86 GAA (0.46) GAACA1CA2CA5ACA9
SCHEMBL4133598 0.84 GAA (0.45) GAACA1CA2CA5ACA9
SCHEMBL4124863 0.84 GAA (0.45) GAACA1CA2CA5ACA9
Benzamide SCHEMBL4004830 0.82 RECQL (0.44) CA2VDRSMN1; SMN2ALDH1A1CYP3A4
SCHEMBL27538902 0.82 ALDH1A1 (0.53) GAACA1CA2CA9ACHE
SCHEMBL4118581 0.81 GAA (0.42) GAACA1CA2CA5ACA9
SCHEMBL1414702 0.81 GAA (0.42) GAACA1CA2CA5ACA9
SCHEMBL777187 0.81 GAA (0.50) GAACA1CA2CA5ACA9
SCHEMBL29367126 0.81 GAA (0.50) GAACA1CA2CA5ACA9
SCHEMBL28019635 0.81 MEN1 (0.44) CA1CA2ALDH1A1MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136779-A Preparation method of fluoro-azabenzene and derivatives thereof 南开大学 2025-06-13 CN claimed
CN-120136779-A Preparation method of fluoro-azabenzene and derivatives thereof 南开大学 2025-06-13 CN disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
CN-112778311-B Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-06-04 CN disclosed
CN-117832622-A Electrolyte of sodium ion battery, sodium ion battery and electronic equipment 惠州市豪鹏科技有限公司 2024-04-05 CN disclosed
US-20220149436-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2022-05-12 US disclosed
US-11283107-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2022-03-22 US disclosed
CN-111217841-B Nitrogen-phosphine ligand coordination type trifluoromethoxy reagent and preparation method and application thereof 中国科学院上海有机化学研究所 2021-06-08 CN disclosed
CN-112778311-A Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2021-05-11 CN disclosed
CN-111217841-A Nitrogen-phosphine ligand coordination type trifluoromethoxy reagent and preparation method and application thereof 中国科学院上海有机化学研究所 2020-06-02 CN disclosed
CN-101421258-A Sulfonyl-substituted bicyclic compounds as PPAR modulators KALYSPSYS INC (US) 2009-04-29 CN disclosed
US-7517884-B2 {5-[4-(4-Trifluoromethyl-phenyl)-piperazine-1-sulfonyl]-indan-2-yl}-acetic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury, diabetes KALYPSYS INC. (US) 2009-04-14 US disclosed
US-7494999-B2 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC (US) 2009-02-24 US disclosed
US-20090029971-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2009-01-29 US disclosed
EP-2012386-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY Mitsubishi Chemical Corporation (JP) 2009-01-07 EP disclosed
EP-1805158-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR Kalypsys, Inc. (US) 2007-07-11 EP disclosed
US-20060205736-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC. 2006-09-14 US disclosed
US-20060167012-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC. 2006-07-27 US disclosed
WO-2006055187-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2006-05-26 WO disclosed
US-4968819-A CATALYTIC SELECTIVE ETHERIFICATION ALKALOIDA VEGYESZETI GYAR (HU) 1990-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167012-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR PPARG, PPARA, PPARD GAA 622/4885CA1 4311/4885CA2 3525/4885
US-20090029971-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR PPARG, PPARA, PPARD GAA 622/4885CA1 4311/4885CA2 3525/4885
US-20060205736-A1 Sulfonyl-substituted bicyclic compounds as modulators of PPAR PPARG, PPARA, PPARD GAA 622/4885CA1 4311/4885CA2 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.